Carthera is a clinical-stage company developing the SonoCloud, a revolutionary system to temporarily open the blood-brain barrier (BBB), and to improve CNS bioavailability of small molecules, ASOs, mAbs and other therapeutics. By using SonoCloud, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases.

SonoCloud is an intracranial implant using low-intensity pulsed ultrasound (LIPU) to temporarily open the blood-brain barrier BBB before or after the injection of therapeutics. This innovative approach is being tested in several clinical programs in Glioblastoma with different chemotherapeutic agents as well as PDL-1 & CTLA-4 antibodies. SonoCloud is now entering the neurodegeneration field with focus on ALS, Huntington Disease and Parkinson Disease.

–  Therapeutic areas: Oncology, Neurodegenerative diseases

–  Based in: Lyon (FRANCE) Office in Boston (USA)

–  Employees: 11 – 50

–  Created in: 2010